drugset / Trial / NCT04792645

Memantine in Body Focused Repetitive Behaviors

NCT04792645

Phase 2 Completed 100 enrolled University of Chicago
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.

Timeline

Start
2021-06-15
Primary completion
2022-07-08
Completion
2022-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 20 mg